Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy

Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy

Primary membranous nephropathy (PMN) is a renal-specific autoimmune disease caused by circulating autoantibodies that target glomerular podocyte antigens (PLA2R/THSD7A). However, very little is known on the molecular mechanisms controlling B cell response in this nephropathy. The present study was a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Giuseppe Stefano Netti, Barbara Infante, Federica Spadaccino, Giulia Godeas, Maria Grazia Corallo, Concetta Prisciandaro, Laura Croce, Mario Rotondi, Loreto Gesualdo, Giovanni Stallone, Giuseppe Grandaliano, Elena Ranieri
Format:	Article
Language:	English
Published:	Wiley 2019-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2019/8483650
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Characterization of BAFF and APRIL subfamily receptors in rainbow trout (Oncorhynchus mykiss). Potential role of the BAFF / APRIL axis in the pathogenesis of proliferative kidney disease.
by: Aitor G Granja, et al.
Published: (2017-01-01)

CLINICAL VALUE OF BAFF AND APRIL CONCENTRATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS
by: T. A. Panafidina, et al.
Published: (2016-07-01)

CLINICAL SIGNIFICANCE OF BAFF/BLyS AND APRIL IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS
by: E. V. Suponitskya, et al.
Published: (2014-10-01)

Serum BAFF levels are associated with the prognosis of idiopathic membranous nephropathy
by: Zhaohui Li, et al.
Published: (2024-12-01)

Telitacicept for lupus nephritis with BAFF and APRIL double positivity in children: a case report
by: Yang Meng, et al.
Published: (2025-05-01)

WCN24-756 POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS
by: James Tumlin, et al.
Published: (2024-04-01)

Prevalence of Autoimmune Thyroiditis and Other Autoimmune Diseases in Relation to Serum BAFF/APRIL Levels in Prolactinoma Patients
by: Özlem Kanburoğlu Meletli, et al.
Published: (2024-01-01)

CCN1 promotes APRIL/BAFF signaling in esophageal squamous cell carcinoma but attenuates it in esophageal adenocarcinoma
by: Lingling Xing, et al.
Published: (2025-01-01)

BAFF and APRIL immunotherapy following Bacille Calmette-Guérin vaccination enhances protection against pulmonary tuberculosis in mice
by: Min Xie, et al.
Published: (2025-02-01)

A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults
by: Rupert Davies, et al.
Published: (2024-11-01)

Impact of NF-κB and reactive oxygen species on intracellular BAFF/APRIL expression in ANCA-associated vasculitis: focusing on the effect of resveratrol
by: Yasuhiro Shimojima, et al.
Published: (2025-06-01)

WCN24-762 UPDATED RESULTS FROM THE RUBY-3 STUDY OF POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS
by: James Tumlin, et al.
Published: (2024-04-01)

BAFF/APRIL expression-guided telitacicept therapy demonstrates superior efficacy in systemic lupus erythematosus patients: a real-world comparative study
by: Li Huang, et al.
Published: (2025-08-01)

Increased BAFF Levels in Children with Acute Brucellosis
by: Emine Hafize Erdeniz, et al.
Published: (2020-03-01)

Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update
by: Giuseppe Stefano Netti, et al.
Published: (2024-12-01)

Association of BAFF gene polymorphisms with multiple sclerosis progression
by: I. V. Smagina, et al.
Published: (2020-02-01)

Key Points in Managing PLA2R-Associated Membranous Nephropathy
by: Raja Ramachandran, et al.
Published: (2024-08-01)

Corrigendum to “Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy” [Kidney International Reports Volume 6, Issue 4, April 2021, Pages 1183-1188]
by: Maxime Teisseyre, et al.
Published: (2024-07-01)

WCN25-1817 THE UNUSAL CASE SERIES OF PLA2R MEMBRANOUS NEPHROPATHY WITH PLA2R ANTIGEN ABSENT AND SERUM PLA2R ANTIBODY PRESENT
by: Anupam Agarwal, et al.
Published: (2025-02-01)

Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice
by: Elena Rinaldi, et al.
Published: (2025-06-01)

Urinary Excretion of Kidney Aquaporins as Possible Diagnostic Biomarker of Diabetic Nephropathy
by: Luigi Rossi, et al.
Published: (2017-01-01)

Current research status of PLA2R and malignancy associated membranous nephropathy
by: Zhu Wan-ting, et al.
Published: (2021-01-01)

INVESTIGATION OF THE EFFECT OF PLA2R1 POLYMORPHISM IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
by: Aida Adıkozalova, et al.
Published: (2024-10-01)

BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis.
by: Xiaohui Zhou, et al.
Published: (2011-01-01)

Modern challenges of iodine nutrition: vegan and vegetarian diets
by: Laura Croce, et al.
Published: (2025-05-01)

The significance of anti-PLA2R antibody in the diagnosis and treatment of primary membranous nephropathy
by: XU Dong-mei, et al.
Published: (2019-01-01)

Serumanti-PLA2R antibody predicted treatment outcome in idiopathic membranous nephropathy
by: Zhang Xue-qin, et al.
Published: (2021-01-01)

INVESTIGATION OF DICER1 AND BAFF GENE MUTATIONS IN B-CELL NON-HODGKIN LYMPHOMA
by: Nurcan Çırak, et al.
Published: (2024-02-01)

Association between BAFF gene polymorphism and systemic lupus erythematosus: a meta-analysis
by: Qing Wu, et al.
Published: (2024-12-01)

A holistic approach to managing cardio-kidney metabolic syndrome: insights and recommendations from the Italian perspective
by: Massimo Iacoviello, et al.
Published: (2025-04-01)

Impact of immunosuppressive therapy on pulmonary perfusion in kidney transplant recipients after COVID-19 illness
by: Barbara Infante, et al.
Published: (2025-06-01)

Study on predictors for treatment efficacy of rituximab in patients with PLA2R-negative primary membranous nephropathy
by: XU Lili, HU Xiaofan, LI Hao, WANG Weiming
Published: (2025-06-01)

Case report: Coexistence of optic neuritis and primary anti-PLA2R-positive membranous nephropathy
by: Xi Wang, et al.
Published: (2025-03-01)

Investigating the Role of BAFF and Its Receptors in Renal Transplant Recipients with Chronic Antibody-Mediated Rejection
by: Shima Afzali, et al.
Published: (2021-01-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

Research progresson correlation of PLA2R1 and HLA gene polymorphisms with susceptibility toidiopathic membranous nephropathy
by: XIE Da-xing, et al.
Published: (2019-01-01)

Differences in serum anti-PLA2R antibody determination in Uygur patients with idiopathic membranous nephropathy in Xinjiang
by: ZHANG Jin, et al.
Published: (2018-01-01)

PLA2R-associated membranous nephropathy associated with renal clear cell carcinoma: one case report
by: Xu Xiao-chang, et al.
Published: (2021-01-01)

Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence
by: Alexandre Destere, et al.
Published: (2024-01-01)

Diagnostic value of PLA2R, THSD7A and IgG subtypes in idiopathic membranous nephropathy
by: XUE Hen, et al.
Published: (2020-01-01)